JP5044754B2 - カンピロバクター・ジェジュニに対するワクチン成分として使用される免疫原莢膜組成物 - Google Patents
カンピロバクター・ジェジュニに対するワクチン成分として使用される免疫原莢膜組成物 Download PDFInfo
- Publication number
- JP5044754B2 JP5044754B2 JP2008532345A JP2008532345A JP5044754B2 JP 5044754 B2 JP5044754 B2 JP 5044754B2 JP 2008532345 A JP2008532345 A JP 2008532345A JP 2008532345 A JP2008532345 A JP 2008532345A JP 5044754 B2 JP5044754 B2 JP 5044754B2
- Authority
- JP
- Japan
- Prior art keywords
- jejuni
- capsule
- campylobacter jejuni
- immunogenic composition
- campylobacter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
シー・ジェジュニ莢膜の免疫原性を示すために、BALB/cマウスを皮下でリン酸塩緩衝塩水(PBS)またはシー・ジェジュニ81−176からの精製した莢膜の何れかによって免疫化した。次の免疫反応は、コントロールとしてウシ血清アルブミン(BSA)を使用して酵素結合イムノソルベント分析(ELISA)によって測定された。この分析では、抗原は精製した莢膜であった。
顕著なIgG反応が、マウスにおいて精製した莢膜に対する反応において観察されたが、多糖に対する免疫は、しばしばT細胞不依存免疫反応を伴う。それゆえ、小児は、典型的に多糖の抗原に対してIgM反応を生じさせるに過ぎないが、成人はIgG、IgAおよびIgM反応を生じさせることができる。
CRM197へ複合化した莢膜により誘発された免疫反応の有効期間を評価するために、血清力価を長期間免疫化されたマウスについてモニターした。この検討において、マウス(n=10)は、14日の間隔(すなわち研究の0日、14日および28日)で、リン酸塩緩衝塩水(PBS)(0μg)、5、10、25または50μgのCRM197へ複合化したシー・ジェジュニ莢膜の3回投与により皮下で免疫化された。血液サンプルを免疫化全研究304目前に間隔をおいて集め、抗莢膜IgGを酵素結合イムノソルベント分析(ELISA)により測定した。
シー・ジェジュニの莢膜−CRM197処方物の有効度の評価をマウスで行った。この実験では、マウスは、14日の間隔(すなわち、0日、14日および28日)で5、10または25μgの莢膜−CRM197複合物の3回投与により免疫化された。コントロール動物は、PBSを受けた。すべての動物(n=7)は、4×109cfuのシー・ジェジュニ81−176により120日目に免疫性をテストされた。免疫性のテスト後、動物は、感染による病気の進展について後続の6日間調べられた。疾患の程度に基づいて、スコアを以下のようにそれぞれの動物について割り当てた。0=見かけの病気なし。1=逆毛がたつ。2=逆毛がたち、身体を丸める。3=死亡。
図4に関して、同様な莢膜特異性血清IgGは、5、10または25gの莢膜−CRM197による免疫化後に見られた。表3に示されるように、防御免疫反応は、防御有効度について用量反応で観察された。疾病インデックスは、25μgの莢膜−CRM197により免疫化された群で最低であり、5μgの莢膜−CRM197複合物により免疫化される群で最高であった。この用量反応は、また体重%における変化が有効度を評価するのに使用されたとき見られた。
本発明の1つの対象は、ヒトにおいて強いかつ有効な免疫反応を誘発するシー・ジェジュニ(C.jejuni)莢膜の能力であるが、禁忌であるギラン・バレ症候群の誘発ではない。ヒトにおける防御免疫を誘発する最適の方法は、マウスおよびモンキーのような動物における検討を先に行うことである。シー・ジェジュニ菌株の単一または混合物からの莢膜を含むそれぞれのワクチン処方物について、限られた量の実験が、最適な有効投与範囲を確かめるのに必要とされる。しかし、抗シー・ジェジュニ治療下痢防御免疫を誘発する予防的方法は、以下の段階を含む。
Claims (5)
- 1つ以上のカンピロバクター・ジェジュニ菌株からのカンピロバクター・ジェジュニ莢膜多糖ポリマーからなり、
該莢膜多糖ポリマーは、式α−D−Gal−(1→[−2)−6d−3−O−Me−α−D−altro−Hep−(1→3)−β−D−GlcNAc−(1→3)α−D−Gal−(1→] nを有する反復三糖構造であり、
前記莢膜多糖ポリマーの末端は、還元的アミノ化により担体分子に複合されているガラクトースであることを特徴とする免疫原組成物。 - 前記担体分子はCRM197である請求項1に記載の免疫原組成物。
- 前記反復三糖構造はGal単位の位置O−2にO−メチル−ホスホルアミドを含むことを特徴とする請求項1又は2に記載の免疫原性組成物。
- 請求項1から3のいずれか1項に記載の免疫原性組成物であって、
a.1投与あたり0.1μgから10mgの投与量範囲でアジュバントとともにまたはなしで前記免疫原組成物を投与する段階、
b.1投与あたり0.1μgから10mgの投与量範囲でアジュバントとともにまたはなしで効果増強量の前記免疫原組成物を投与する段階
からなる抗カンピロバクター・ジェジュニ免疫を生成する方法に用いられる免疫原性組成物。 - 前記アジュバントが、LTR 192G、水酸化アルミニウム、RC529E、QS21、E294、オリゴデオキシヌクレオチド(ODN)、CpG−含有オリゴデオキシヌクレオチド、リン酸アルミニウムからなる群から選ばれる請求項4に記載の免疫原性組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72208605P | 2005-09-21 | 2005-09-21 | |
US60/722,086 | 2005-09-21 | ||
PCT/US2006/036619 WO2007038122A2 (en) | 2005-09-21 | 2006-09-20 | Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009508962A JP2009508962A (ja) | 2009-03-05 |
JP5044754B2 true JP5044754B2 (ja) | 2012-10-10 |
Family
ID=37900259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008532345A Active JP5044754B2 (ja) | 2005-09-21 | 2006-09-20 | カンピロバクター・ジェジュニに対するワクチン成分として使用される免疫原莢膜組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9084809B2 (ja) |
EP (1) | EP1933865B1 (ja) |
JP (1) | JP5044754B2 (ja) |
AU (1) | AU2006295017B2 (ja) |
CA (1) | CA2623400C (ja) |
WO (1) | WO2007038122A2 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003254665C1 (en) * | 2002-08-01 | 2010-08-19 | National Research Council Of Canada | Campylobacter glycans and glycopeptides |
US9999591B2 (en) | 2005-09-21 | 2018-06-19 | The United States Of America As Represented By The Secretary Of The Navy | Immunogenic composition against Campylobacter jejuni |
EP2021020B1 (en) * | 2006-05-12 | 2013-03-20 | The United States Of America, As Represented By The Secretary Of The Navy | Secreted campylobacter flagella coregulated proteins as immunogens |
JP6030282B2 (ja) * | 2007-07-27 | 2016-11-24 | アメリカ合衆国 | カンピロバクター・ジェジュニに対する免疫原として使用するための莢膜組成物 |
ES2528648T3 (es) | 2007-09-11 | 2015-02-11 | University Of Guelph | Inmunógenos polisacáridos de la Clostridium Difficile |
PT2411503T (pt) | 2009-03-27 | 2017-11-15 | Eidgenössische Technische Hochschule Zürich | Salmonella enterica que apresenta n-glicano de c. jejuni ou derivados do mesmo |
DE102009060999A1 (de) * | 2009-06-24 | 2011-01-05 | German Gresser | Energieoptimiertes Elektrofahrzeug mit autarker Stromversorgung und Verfahren zur Stromerzeugung, bevorzugt aus kinetischer und Gravitationsenergie |
US9308246B2 (en) | 2010-05-28 | 2016-04-12 | The United States Of America As Represented By The Secretary Of The Navy | Capsule composition for use as immunogen against Campylobacter jejuni |
CA2957430C (en) * | 2014-08-07 | 2021-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Immunogenic composition against campylobacter jejuni |
EP3197485B1 (en) * | 2014-09-24 | 2022-11-02 | The United States of America as Represented by The Secretary of the Navy | Combined enterotoxigenic escherichia coli and campylobacter jejuni recombinant construct |
WO2016073773A1 (en) * | 2014-11-05 | 2016-05-12 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
US10500261B2 (en) | 2014-11-05 | 2019-12-10 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761283A (en) * | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5681736A (en) * | 1994-10-05 | 1997-10-28 | Antex Biologics, Inc. | Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same |
US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
WO2005017129A1 (en) * | 2003-08-18 | 2005-02-24 | National Research Council Of Canada | Phosphoramide and uses thereof |
-
2006
- 2006-09-20 EP EP06815015.0A patent/EP1933865B1/en active Active
- 2006-09-20 US US11/524,057 patent/US9084809B2/en not_active Expired - Fee Related
- 2006-09-20 JP JP2008532345A patent/JP5044754B2/ja active Active
- 2006-09-20 WO PCT/US2006/036619 patent/WO2007038122A2/en active Application Filing
- 2006-09-20 CA CA2623400A patent/CA2623400C/en active Active
- 2006-09-20 AU AU2006295017A patent/AU2006295017B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2006295017A1 (en) | 2007-04-05 |
WO2007038122A2 (en) | 2007-04-05 |
US20070065461A1 (en) | 2007-03-22 |
WO2007038122A3 (en) | 2007-08-30 |
CA2623400C (en) | 2015-04-07 |
US9084809B2 (en) | 2015-07-21 |
EP1933865A4 (en) | 2010-12-22 |
AU2006295017B2 (en) | 2010-06-17 |
CA2623400A1 (en) | 2007-04-05 |
EP1933865B1 (en) | 2016-03-09 |
EP1933865A2 (en) | 2008-06-25 |
JP2009508962A (ja) | 2009-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5044754B2 (ja) | カンピロバクター・ジェジュニに対するワクチン成分として使用される免疫原莢膜組成物 | |
Berry et al. | Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses | |
EP0939647B2 (en) | Neisseria meningitidis serogroup b glycoconjugates and methods of using the same | |
TWI751513B (zh) | E. coli O-抗原多醣生物結合物、其製備方法及其使用方法 | |
ES2200067T3 (es) | Fragmentos de polisacaridos antigenicos de tipo ii y tipo iii de streptococcus del grupo b, que tienen una estructura terminal 2,5-anhidro-d-manosa, y su vacuna conjugada. | |
Khatun et al. | An overview of structural features of antibacterial glycoconjugate vaccines that influence their immunogenicity | |
TWI771663B (zh) | E. coli O-抗原多醣生物結合物之製備方法、其組合物及其使用方法 | |
JP2010532793A (ja) | コンジュゲートワクチン用修飾多糖 | |
EP2185189B1 (en) | Capsule composition for use as immunogen against campylobacter jejuni | |
US7700578B2 (en) | Capsule composition for use as immunogen against Campylobacter jejuni | |
Cross | Hit ‘em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target | |
JP2007524623A (ja) | Y群髄膜炎菌ワクチン及びそれらの髄膜炎菌組合せワクチン | |
Szu et al. | Induction of Serum Vibriocidal Antibodies by O‐Specific Polysaccharide–Protein Conjugate Vaccines for Prevention of Cholera | |
US20160136285A1 (en) | An isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by gram-negative bacteria | |
Korcová et al. | Immunomodulative properties of conjugates composed of detoxified lipopolysaccharide and capsular polysaccharide of Vibrio cholerae O135 bound to BSA-protein carrier | |
Santana Medero et al. | Vaccines against Bacterial Pathogens: A General Overview | |
Schneerson et al. | VACCINES FOR PREVENTION OF ENTERIC BACTERIAL INFECTIONS CAUSED BY SALMONELLAE | |
World Health Organization | The immunological basis for immunization series: module 14: cholera | |
Robbins | Prevention of Invasive Bacterial Diseases by Immunization with Polysaccharide-Protein Conjugates JB Robbins, R. Schneerson, SC Szu, A. Fattom, Y. Yang, T. Lagergard, C. Chu, and US Sørensen Laboratory of Development and Molecular Immunity, National Institute of Child | |
Szu et al. | Vaccines for prevention of enteric bacterial infections caused by Salmonellae | |
Szu et al. | Escherichia coli O157 | |
Pozsgay | Bacterial polysaccharide-protein conjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110719 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120126 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120229 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120229 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120409 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120508 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120606 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150727 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5044754 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |